1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > ARCHIVE
ARCHIVE
- Fukuda Denshi to Boost Sales to \100 Billion in 2010
June 25, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
June 18, 2001
- Patient-Oriented Healthcare Discussed: JPMA Seminar
June 18, 2001
- REGULATORY NEWS IN BRIEF
June 18, 2001
- Taxol Approved for Gastric Cancer
June 18, 2001
- All Parties Should Cooperate to Establish Desirable Trade Practices: EAD Director
June 18, 2001
- DIAGNOSTIC NEWS IN BRIEF
June 18, 2001
- Drug Safety Measures by Korosho Must Meet Int'l Standards: PMSB
June 18, 2001
- FFITMA Reorganized
June 18, 2001
- Mefenamic Acid Should Not Be Used for Fevers Associated with Influenza: CDFS
June 18, 2001
- JEOL: New High Resolution Scanning Electron Microscope
June 18, 2001
- Matsumotokiyoshi Ties Up with Takada Yakkyoku
June 18, 2001
- GE Marquette Medical Systems Japan: Dash 4000 System
June 18, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIE -2-
June 18, 2001
- Nicolet Biomedical, GE Marquette Medical Systems Japan Reinforce Alliance
June 18, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -3-
June 18, 2001
- OTC NEWS IN BRIEF
June 18, 2001
- Tsumura to Jointly Study Cultivation of Crude Drugs with Chinese Firm
June 18, 2001
- Pharmacists Regarded as 4th Most Reliable: Survey
June 18, 2001
- Discussions Must Be Restarted from 10% R-zone: Mr Matsutani
June 18, 2001
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…